Pharmacological induction of interferon type i activity following treatment with rituximab determines clinical response in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 6, 2011, Pages 1153-1159

  Vosslamber, Saskia ^a   Raterman, Hennie G ^a   Van Der Pouw Kraan, Tineke C T M ^a   Schreurs, Marco W J ^a   Von Blomberg, B Mary E ^a   Nurmohamed, Michael T ^b   Lems, Willem F ^a,b   Dijkmans, Ben A C ^a,b   Voskuyl, Alexandre E ^a   Verweij, Cornelis L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Jan Van Breemen Research Institute/Reade   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMASTINE; COMPLEMENTARY DNA; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC REGULATION; HUMAN; INTERFERON TYPE 1 GENE; MALE; MICROARRAY ANALYSIS; NETHERLANDS; PHARMACOGENOMICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79955823796     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.147199     Document Type: Article

References (37)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003 ; 423 : 356-61. (Pubitemid 40852711) (Pubitemid 40852711)
2. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008 ; 223 : 7-19. (Pubitemid 351986171) (Pubitemid 351986171)
3. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007 ; 370 : 1861-74. (Pubitemid 350180008) (Pubitemid 350180008)
4. Verweij CL. Predicting the future of anti-tumor necrosis factor therapy. Arthritis Res Ther 2009 ; 11 : 115.
5. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 ; 54 : 2793-806. (Pubitemid 44497758) (Pubitemid 44497758)
6. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350 : 2572-81. (Pubitemid 38758544) (Pubitemid 38758544)
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006 ; 54 : 1390-400.
8. Caporali R, Caprioli M, Bobbio-Pallavicini F, et al. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009 ; 8 : 591-4.
9. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006 ; 54 : 723-32.
10. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 2005 ; 8 : 175-92.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 ; 31 : 315-24. (Pubitemid 18091653) (Pubitemid 18091653)
12. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 ; 38 : 44-8.
13. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003 ; 19 : 185-93. (Pubitemid 36181903) (Pubitemid 36181903)
14. Rainer J, Sanchez-Cabo F, Stocker G, et al. CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res 2006 ; 34 : W498-503. (Pubitemid 44529821) (Pubitemid 44529821)
15. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001 ; 98 : 5116-21. (Pubitemid 32397092) (Pubitemid 32397092)
16. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genomewide expression patterns. Proc Natl Acad Sci USA 1998 ; 95 : 14863-8. (Pubitemid 29003722) (Pubitemid 29003722)
17. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003 ; 34 : 267-73. (Pubitemid 36792858) (Pubitemid 36792858)
18. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005 ; 102 : 15545-50. (Pubitemid 41528093) (Pubitemid 41528093)
19. Baechler E C, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003 ; 100 : 2610-15. (Pubitemid 36297546) (Pubitemid 36297546)
20. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010 ; 62 : 3607-14.
21. Cantaert T, van Baarsen LG, Wijbrandts CA, et al. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology (Oxford) 2010 ; 49 : 156-66.
22. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007; 66 : 1008-14. (Pubitemid 47122311) (Pubitemid 47122311)
23. Reis EA, Athanazio DA, Lima I, et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 2009 ; 29 : 469-75.
24. Dass S, Vital EM, Emery P. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006 ; 7 : 2559-70. (Pubitemid 44932458) (Pubitemid 44932458)
25. Jego G, Pascual V, Palucka AK, et al. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005 ; 8 : 124-39.
26. Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003 ; 19 : 225-34. (Pubitemid 37011337) (Pubitemid 37011337)
27. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009 ; 388 : 621-5.
28. Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006 ; 38 : 550-5.
29. Sigurdsson S, Nordmark G, Garnier S, et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008 ; 17 : 2868-76.
30. Treschow AP, Teige I, Nandakumar KS, et al. Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum 2005 ; 52 : 3739-48. (Pubitemid 41798210) (Pubitemid 41798210)
31. de Hooge AS, van de Loo FA, Koenders MI, et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis Rheum 2004 ; 50 : 2014-23. (Pubitemid 38725114) (Pubitemid 38725114)
32. van Holten J, Plater-Zyberk C, Tak PP. Interferon-beta for treatment of rheumatoid arthritis? Arthritis Res 2002 ; 4 : 346-52.
33. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010 ; 62 : 222-33.
34. van Baarsen LG, Wijbrandts CA, Rustenburg F, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010 ; 12 : R11.
35. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005 ; 102 : 3372-7. (Pubitemid 40328052) (Pubitemid 40328052)
36. Yarilina A, Park-Min KH, Antoniv T, et al. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 2008 ; 9 : 378-87. (Pubitemid 351405107) (Pubitemid 351405107)
37. van Baarsen LG, Wijbrandts CA, Timmer TC, et al. Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum 2010 ; 62 : 1602-7.